Utility of measuring (1,3)-β-D-Glucan in cerebrospinal fluid for diagnosis of fungal central nervous system infection

Jennifer L. Lyons, Kiran T. Thakur, Rick Lee, Tonya Watkins, Carlos A. Pardo, Kathryn A. Carson, Barbara Markley, Malcolm A. Finkelman, Kieren A. Marr, Karen L. Roos, Sean X. Zhang

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

(1-3)-β-D-Glucan (BDG) from cerebrospinal fluid (CSF) is a promising marker for diagnostic and prognostic aid of central nervous system (CNS) fungal infection, but its relationship to serum values has not been studied. Herein, we detected BDG from CSF at levels 2-fold lower than those in serum in patients without evidence of fungal disease but 25-fold higher than those in in serum in noncryptococcal CNS fungal infections. CSF BDG may be a useful biomarker in the evaluation of fungal CNS disease.

Original languageEnglish (US)
Pages (from-to)319-322
Number of pages4
JournalJournal of clinical microbiology
Volume53
Issue number1
DOIs
StatePublished - Jan 1 2015

ASJC Scopus subject areas

  • Microbiology (medical)

Fingerprint Dive into the research topics of 'Utility of measuring (1,3)-β-D-Glucan in cerebrospinal fluid for diagnosis of fungal central nervous system infection'. Together they form a unique fingerprint.

  • Cite this

    Lyons, J. L., Thakur, K. T., Lee, R., Watkins, T., Pardo, C. A., Carson, K. A., Markley, B., Finkelman, M. A., Marr, K. A., Roos, K. L., & Zhang, S. X. (2015). Utility of measuring (1,3)-β-D-Glucan in cerebrospinal fluid for diagnosis of fungal central nervous system infection. Journal of clinical microbiology, 53(1), 319-322. https://doi.org/10.1128/JCM.02301-14